SYK has also been shown to be associated with resistance to FLT3-ITD-targeted therapy, and inhibition of FLT3-ITD with quizartinib combined with inhibition of SYK was shown to be more effective than FLT3 inhibition alone in FLT3-ITD-positive models of AML [10]. This evidence concerns the gene SYK and acute myeloid leukemia.